ATE268382T1 - MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2 - Google Patents

MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2

Info

Publication number: ATE268382T1
Authority: AT; Austria
Prior art keywords: cdr; seq; human; chain; ßcdr
Prior art date: 1997-03-19

Application number

AT98105047T

Other languages

English (en)

Inventor

Nakamura Kazuyasu

Hanai Nobuo

Original Assignee

Kyowa Hakko Kogyo Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-19

Filing date

1998-03-19

Publication date

2004-06-15

1998-03-19 Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk

2004-06-15 Application granted granted Critical

2004-06-15 Publication of ATE268382T1 publication Critical patent/ATE268382T1/de

Links

GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 title abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 3
108091035707 Consensus sequence Proteins 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Endocrinology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT98105047T 1997-03-19 1998-03-19 MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2 ATE268382T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP06698197A JP4550947B2 (ja)	1997-03-19	1997-03-19	ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体

Publications (1)

Publication Number	Publication Date
ATE268382T1 true ATE268382T1 (de)	2004-06-15

Family

ID=13331716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98105047T ATE268382T1 (de)	1997-03-19	1998-03-19	MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2

Country Status (7)

Country	Link
EP (1)	EP0882794B1 (de)
JP (1)	JP4550947B2 (de)
AT (1)	ATE268382T1 (de)
AU (1)	AU751948B2 (de)
CA (1)	CA2226400C (de)
DE (1)	DE69824234T2 (de)
ES (1)	ES2219802T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6407734B1 (en)	1994-10-31	2002-06-18	Nec-Mitsubishi Electric Visual Systems Corporation	Power supply system capable of reducing power consumption during interruption of an external input signal given to an operating circuit
US7241568B2 (en)	1996-04-03	2007-07-10	Kyowa Hakko Kogyo Co., Ltd.	Anti-fibroblast growth factor-8 monoclonal antibody
DK1176195T3 (da)	1999-04-09	2013-06-24	Kyowa Hakko Kirin Co Ltd	Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US6693176B1 (en)	1999-07-23	2004-02-17	University Of Massachusetts	Antitumor antibodies, proteins, and uses thereof
AU7449200A (en) *	1999-09-30	2001-04-30	Kyowa Hakko Kogyo Co. Ltd.	Derivatives of antibody against ganglioside gm2
AU2016204535C1 (en) *	2000-04-12	2017-02-23	Laboratoire Français Du Fractionnement Et Des Biotechnologies	Anti-D monoclonal antibodies
FR2807767B1 (fr) *	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
JP2001299349A (ja) *	2000-04-19	2001-10-30	Suntory Ltd	新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013224B1 (ru) *	2000-10-06	2010-04-30	Киова Хакко Кирин Ко., Лтд.	Клетки, продуцирующие композиции антител
AU2002346127B2 (en) *	2001-06-28	2008-05-29	Kyowa Hakko Kirin Co., Ltd.	Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
WO2003049704A2 (en)	2001-12-11	2003-06-19	University Of Massachusetts	Antibodies to treat cancer
ATE429249T1 (de) *	2001-12-28	2009-05-15	Kyowa Hakko Kogyo Kk	Anti-fgf-8 antikörper gegen arthritis
AU2003236017B2 (en)	2002-04-09	2009-03-26	Kyowa Kirin Co., Ltd.	Drug containing antibody composition
US20040115204A1 (en)	2002-12-11	2004-06-17	Fanger Gary R.	Antibodies to treat cancer
AU2004279736A1 (en) *	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Antibody composition specifically binding to ganglioside GM2
US7691810B2 (en)	2003-10-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Method of producing recombinant antithrombin III composition
EP2107115A1 (de)	2007-01-24	2009-10-07	Kyowa Hakko Kirin Co., Ltd.	Genetisch rekombinante antikörperzusammensetzung zur anbindung insbesondere an gangliosid gm2
FR2953841B1 (fr) *	2009-12-16	2011-12-30	Centre Nat Rech Scient	Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
EP2543727B1 (de)	2010-03-02	2016-08-31	Kyowa Hakko Kirin Co., Ltd.	Modifizierte antikörperzusammensetzung
JP6310397B2 (ja) *	2012-12-06	2018-04-11	国立大学法人金沢大学	中皮腫の治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU669379B2 (en) *	1992-09-07	1996-06-06	Kyowa Hakko Kirin Co., Ltd.	Humanized antibodies

1997
- 1997-03-19 JP JP06698197A patent/JP4550947B2/ja not_active Expired - Lifetime
1998
- 1998-03-19 EP EP98105047A patent/EP0882794B1/de not_active Expired - Lifetime
- 1998-03-19 AT AT98105047T patent/ATE268382T1/de not_active IP Right Cessation
- 1998-03-19 CA CA002226400A patent/CA2226400C/en not_active Expired - Lifetime
- 1998-03-19 DE DE69824234T patent/DE69824234T2/de not_active Expired - Lifetime
- 1998-03-19 ES ES98105047T patent/ES2219802T3/es not_active Expired - Lifetime
- 1998-03-19 AU AU59420/98A patent/AU751948B2/en not_active Expired

Also Published As

Publication number	Publication date
EP0882794B1 (de)	2004-06-02
DE69824234D1 (de)	2004-07-08
JPH10257893A (ja)	1998-09-29
AU5942098A (en)	1998-10-01
EP0882794A3 (de)	1999-06-16
JP4550947B2 (ja)	2010-09-22
CA2226400C (en)	2008-12-02
CA2226400A1 (en)	1998-09-19
AU751948B2 (en)	2002-09-05
EP0882794A2 (de)	1998-12-09
ES2219802T3 (es)	2004-12-01
DE69824234T2 (de)	2005-06-23

Publication	Publication Date	Title
ATE268382T1 (de)	2004-06-15	MENSCHLICHE-ßCDR-GRAFTEDß-ANTIKÖRPER GEGEN GANGLIOSID GM2
FR12C0004I1 (de)	2012-02-24
WO1998050433A3 (en)	1999-02-04	Human monoclonal antibodies to epidermal growth factor receptor
TR200200735T2 (tr)	2002-06-21	CTLA-4 için insan monoklonal antikorları
JP2004527212A5 (de)	2011-03-10
GEP20105118B (en)	2010-11-25	Anti-vegf antibodies
NZ503763A (en)	2003-01-31	Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NZ331014A (en)	2000-01-28	Anticoagulant agents useful in treatment of thrombosis
CA2267072A1 (en)	1998-04-09	Reconstituted human anti-hm1.24 antibody
ATE373712T1 (de)	2007-10-15	Natürlicher menschlicher antikörper
WO1998018826A3 (en)	1998-06-18	Anti-CCR5 antibodies and methods of use therefor
NZ514887A (en)	2003-06-30	IBD-associated microbial antigens and methods of using same
EE05497B1 (et)	2011-12-15	Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
EP1530579A4 (de)	2006-02-08	Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung
CA2361987A1 (en)	2000-08-31	Goodpasture antigen binding protein
DE69922834D1 (de)	2005-01-27	Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
AU4876196A (en)	1996-09-18	A process for the preparation of factor ix from biological sources
EP0816504A3 (de)	1999-01-07	Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
AU3582593A (en)	1993-08-03	Antigen recognized by patients with antibody associated lambert-eaton myasthenic syndrome (LEMS), DNA encoding same and uses thereof
NO972522L (no)	1997-08-06	Monoklonale antistoffer med immunoundertrykkende aktivitet
DE59608073D1 (de)	2001-12-06	Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ATE441713T1 (de)	2009-09-15	Tumorantigenprotein und dessen verwendung
EP1191096A4 (de)	2004-06-02	Neues protein und dessen dns
DE59207362D1 (de)	1996-11-21	Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
SE9600436D0 (sv)	1996-02-06	Vaccine against hantavirus

Legal Events

Date	Code	Title	Description
2004-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties